Illumina, a prominent biotech firm specializing in gene-sequencing technology, is currently navigating a series of significant challenges. Recent geopolitical tensions, policy shifts, and emerging competitors have collectively contributed to a complex and uncertain business environment for the company.
Impact of U.S.-China Trade Relations
- Inclusion on China’s Unreliable Entities List: On February 4, 2025, China’s Ministry of Commerce added Illumina to its “Unreliable Entities List,” citing alleged discriminatory measures against Chinese enterprises. This designation could lead to restrictions affecting Illumina’s operations in China, a market that accounts for approximately 7% of its revenue. In response, Illumina has expressed its commitment to resolving the issue and continues to engage with Chinese authorities.
